PAX Therapeutics, Inc
PAX Therapeutics is a US-based biotechnology company developing a locally delivered AAV2-based gene therapy to improve healing of tendon and ligament injuries in humans and animals. The company has completed preclinical studies and GLP toxicology/dose-range work in support of an anticipated IND filing and is preparing early-phase clinical evaluation.
Industries
N/A
Products
PAX-001 (AAV2-based local gene therapy)
An AAV2 vector encoding a growth factor designed for local delivery to tendons and ligaments to stimulate vascularization and Type I collagen production and improve repair outcomes.
PAX-001 (AAV2-based local gene therapy)
An AAV2 vector encoding a growth factor designed for local delivery to tendons and ligaments to stimulate vascularization and Type I collagen production and improve repair outcomes.
Expertise Areas
- Gene therapy for musculoskeletal repair
- Preclinical tendon and ligament models
- IND-enabling study execution
- Early-phase clinical trial design (Phase 1/1b)
Key Technologies
- AAV2 vector-based gene delivery
- Local intratendinous/intraligamentous injection
- Ultrasound-guided percutaneous injection
- GLP toxicology and dose-range studies